Related references
Note: Only part of the references are listed.Circulating Fibroblast Growth Factor 21 Levels Predict Progressive Kidney Disease in Subjects With Type 2 Diabetes and Normoalbuminuria
C. H. Lee et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes
Markus Herrmann et al.
DIABETES CARE (2015)
The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study
Kwok-Leung Ong et al.
DIABETOLOGIA (2015)
Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction
Janka Hindricks et al.
CLINICAL ENDOCRINOLOGY (2014)
Prognostic value of multiple emerging biomarkers in cardiovascular risk prediction in patients with stable cardiovascular disease
Namanjeet Ahluwalia et al.
ATHEROSCLEROSIS (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives
Y. C. Woo et al.
CLINICAL ENDOCRINOLOGY (2013)
Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice
H. W. Kim et al.
ENDOCRINOLOGY (2013)
Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones
Paul A. Dutchak et al.
CELL (2012)
Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes
Kwok Leung Ong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Association between serum fibroblast growth factor 21 and diabetic nephropathy
Wei-Xia Jian et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ
Wei Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Do novel biomarkers add to existing scores of total cardiovascular risk?
Guy De Backer et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2012)
High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes A 5.4-year population-based prospective study in Chinese subjects
Cheng Chen et al.
DIABETES CARE (2011)
Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
T. M. E. Davis et al.
DIABETOLOGIA (2011)
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
Michael J. Pencina et al.
STATISTICS IN MEDICINE (2011)
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Ffolliott M. Fisher et al.
DIABETES (2010)
Serum Levels of the Adipokine FGF21 Depend on Renal Function
Sebastian Stein et al.
DIABETES CARE (2009)
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Kushwin Rajamani et al.
LANCET (2009)
An update on the lipid nephrotoxicity hypothesis
Xiong Z. Ruan et al.
NATURE REVIEWS NEPHROLOGY (2009)
Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans
Xinmei Zhang et al.
DIABETES (2008)
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
Michael J. Pencina et al.
STATISTICS IN MEDICINE (2008)
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
A. C. Keech et al.
LANCET (2007)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
FGF-21 as a novel metabolic regulator
A Kharitonenkov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]
R. Scott et al.
CARDIOVASCULAR DIABETOLOGY (2005)
Share Paper
